Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

LYRA


Top 10 Correlated ETFs

LYRA


Top 10 Correlated Stocks

LYRA


In the News

07:00 03 Oct 2022 LYRA

Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting

WATERTOWN, Mass. , Aug. 29, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that the company will present additional Phase 2 results from the LANTERN study for LYR‑210, the company's lead product candidate for chronic rhinosinusitis, at the 68th Annual Meeting of the American Rhinologic Society (ARS), taking place September 9-10, 2022 in Philadelphia.

09:47 03 Oct 2022 LYRA

Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Lags Revenue Estimates

Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of -26.47% and 92.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

07:00 03 Oct 2022 LYRA

Lyra Therapeutics to Present at Upcoming Investor Conferences

WATERTOWN, Mass. , May 26, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Maria Palasis, Ph.D.

12:46 03 Oct 2022 LYRA

Lyra Therapeutics: Progress In The Clinic

Phase 3 trials for LYR-210 are underway. LYR-210 has shown an excellent efficacy and safety profile.

09:47 03 Oct 2022 LYRA

Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates

Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of 41.30% and 114.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

06:31 03 Oct 2022 LYRA

7 Stocks to Watch for Major Insider Trading Clues

These seven stocks show varying degrees of insider trading, which can provide a hint regarding each company or fund's performance. The post 7 Stocks to Watch for Major Insider Trading Clues appeared first on InvestorPlace.

12:11 03 Oct 2022 LYRA

Lyra Therapeutics Stock Surges On Equity Raise Of $100M

Lyra Therapeutics Inc (NASDAQ: LYRA) has announced a private placement of approximately $100.5 million. The Company has offered 18.8 million common shares at $4.22 per share and pre-funded warrants to purchase an aggregate of 5 million shares with an exercise price of $0.001 per share,.

12:37 03 Oct 2022 LYRA

Lyra Therapeutics Kickstarts LYR-210 Pivotal Program in Surgically Naïve Chronic Rhinosinusitis Patients

Lyra Therapeutics Inc (NASDAQ: LYRA) has initiated its Phase 3 ENLIGHTEN I trial of LYR-210 in adult, surgically naïve chronic rhinosinusitis (CRS) patients. LYR-210 is designed to be administered in a brief, non-invasive, in-office procedure and deliver up to six months of continuous anti-inflammatory medication to the sinonasal passages.

07:00 03 Oct 2022 LYRA

Lyra Therapeutics to Present at Upcoming Virtual Investor Conferences

WATERTOWN, Mass., Nov. 11, 2021 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Maria Palasis, Ph.D.

10:20 03 Oct 2022 LYRA

Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q3 2021 Results - Earnings Call Transcript

Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q3 2021 Results - Earnings Call Transcript

Financial details

Company Rating
Buy
Market Cap
159.45M
Income
-42.72M
Revenue
5.64M
Book val./share
2.16
Cash/share
2.59
Dividend
-
Dividend %
-
Employees
60
Optionable
No
Shortable
Yes
Earnings
07 Nov 2022
P/E
-1.53
Forward P/E
-
PEG
-0.57
P/S
11.56
P/B
2.31
P/C
2.01
P/FCF
-2.24
Quick Ratio
2.18
Current Ratio
2.28
Debt / Equity
0
LT Debt / Equity
0
-
-
EPS (TTM)
-3.29
EPS next Y
-
EPS next Q
-
EPS this Y
29.22%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
1988.33%
EPS Q/Q
-48.44%
-
-
-
-
SMA20
-16.67%
SMA50
-16.67%
SMA100
-16.67%
Inst Own
100%
Inst Trans
61.32%
ROA
-90%
ROE
-102%
ROC
-1.45%
Gross Margin
-
Oper. Margin
-759%
Profit Margin
-758%
Payout
-
Shs Outstand
31.83M
Shs Float
10.74M
-
-
-
-
Target Price
15
52W Range
3.3-9.54
52W High
-42.11%
52W Low
+73.67%
RSI
36
Rel Volume
0.27
Avg Volume
37.1K
Volume
9.99K
Perf Week
-7.79%
Perf Month
-12.73%
Perf Quarter
-16.37%
Perf Half Y
25.54%
-
-
-
-
Beta
-0.626574
-
-
Volatility
0.15%, 0.38%
Prev Close
3.99%
Price
5.21
Change
2.16%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2020-12-31 2021-12-31
Revenue per share
00.02
Net income per share
-2.58-3.35
Operating cash flow per share
-2.46-1.99
Free cash flow per share
-2.67-1.99
Cash per share
8.683.52
Book value per share
8.672.64
Tangible book value per share
8.672.64
Share holders equity per share
8.672.64
Interest debt per share
0.110.11
Market cap
90.8M45.51M
Enterprise value
17.19M1.21M
P/E ratio
-4.1-1.05
Price to sales ratio
0159.67
POCF ratio
-4.29-1.76
PFCF ratio
-3.96-1.76
P/B Ratio
1.221.33
PTB ratio
1.221.33
EV to sales
04.25
Enterprise value over EBITDA
-0.78-0.03
EV to operating cash flow
-0.81-0.05
EV to free cash flow
-0.75-0.05
Earnings yield
-0.24-0.96
Free cash flow yield
-0.25-0.57
Debt to equity
00.01
Debt to assets
0.080.37
Net debt to EBITDA
3.331.02
Current ratio
15.542.63
Interest coverage
00
Income quality
0.960.59
Dividend Yield
00
Payout ratio
00
Sales general and administrative to revenue
049.85
Research and developement to revenue
0104.19
Intangibles to total assets
00
Capex to operating cash flow
0.080
Capex to revenue
00
Capex to depreciation
-18.680
Stock based compensation to revenue
00
Graham number
22.4214.1
ROIC
-0.29-1.19
Return on tangible assets
-0.27-0.79
Graham Net
7.951.94
Working capital
71.03M29.67M
Tangible asset value
00
Net current asset value
69.58M27.37M
Invested capital
0.010.04
Average receivables
00
Average payables
922K2.02M
Average inventory
00
Days sales outstanding
00
Days payables outstanding
00
Days of inventory on hand
00
Receivables turnover
00
Payables turnover
00
Inventory turnover
00
ROE
-0.3-1.27
Capex per share
-0.210

Quarterly Fundamentals Overview

Last date of statement is 2022-03-31 for Q1

Metric History 2021-03-312021-06-302021-09-302021-12-31 2022-03-31
Revenue per share
0000.020.41
Net income per share
-0.6-0.85-0.85-1.05-0.54
Operating cash flow per share
-0.590.26-0.79-0.87-0.92
Free cash flow per share
-0.680.21-0.83-0.69-0.92
Cash per share
5.115.314.473.522.59
Book value per share
5.224.433.632.642.16
Tangible book value per share
5.224.433.632.642.16
Share holders equity per share
5.224.433.632.642.16
Interest debt per share
0.170.150.130.110.09
Market cap
150.04M104.32M118.63M56.69M52.3M
Enterprise value
86.14M37.24M62.2M12.39M19.74M
P/E ratio
-4.81-2.36-2.68-1.04-1.86
Price to sales ratio
008.47K220.579.74
POCF ratio
-19.7730.86-11.5-5.02-4.39
PFCF ratio
-17.1537.85-10.95-6.3-4.36
P/B Ratio
2.221.812.511.651.86
PTB ratio
2.221.812.511.651.86
EV to sales
004.44K48.223.68
Enterprise value over EBITDA
-11.1-3.46-5.81-0.91-2.94
EV to operating cash flow
-11.3511.01-6.03-1.1-1.66
EV to free cash flow
-9.8413.51-5.74-1.38-1.64
Earnings yield
-0.05-0.11-0.09-0.24-0.13
Free cash flow yield
-0.060.03-0.09-0.16-0.23
Debt to equity
0.020.020.010.010
Debt to assets
0.070.250.30.370.41
Net debt to EBITDA
8.236.235.273.254.85
Current ratio
16.1511.873.432.632.28
Interest coverage
0000-501.86
Income quality
0.97-0.310.930.831.7
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0028713.880.72
Research and developement to revenue
00505.540.241.58
Intangibles to total assets
00000
Capex to operating cash flow
0.15-0.180.0500.01
Capex to revenue
00-36.930-0.02
Capex to depreciation
-16.57-2.06-1.480-0.33
Stock based compensation to revenue
0052.3600.16
Graham number
8.419.28.337.895.12
ROIC
-0.11-0.16-0.22-0.37-0.24
Return on tangible assets
-0.11-0.14-0.16-0.25-0.15
Graham Net
4.693.862.891.941.41
Working capital
63.18M64.17M43.11M29.67M22.75M
Tangible asset value
00000
Net current asset value
61.99M51.24M40.31M27.37M21.37M
Invested capital
0.030.030.040.040.04
Average receivables
00000
Average payables
2.15M2.51M3.02M3.13M2.77M
Average inventory
00000
Days sales outstanding
000083.85
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00001.07
Payables turnover
00000
Inventory turnover
00000
ROE
-0.12-0.19-0.23-0.4-0.25
Capex per share
-0.09-0.05-0.040-0.01

Frequently Asked Questions

What is Lyra Therapeutics, Inc. stock symbol ?

Lyra Therapeutics, Inc. is a US stock , located in Watertown of Massachusetts and trading under the symbol LYRA

What is Lyra Therapeutics, Inc. stock quote today ?

Lyra Therapeutics, Inc. stock price is $5.21 today.

Is Lyra Therapeutics, Inc. stock public?

Yes, Lyra Therapeutics, Inc. is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap